- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLL
Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Christopher Pleyer, MD, The National Heart, Lung, and Blood Institute, discusses the safety and effectiveness of ibrutinib (Imbruvica) plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia (CLL).
The combination of ibrutinib and short‐course fludarabine appears to be safe in patients with CLL, according to results from a phase 2 trial. No excess toxicities were observed in this patient population, says Pleyer; prolonged T-cell depletion was not reported.
The combination appears to be effective, with patients achieving high rates of complete remission (CR). However, longer follow-up is needed to determine whether these high rates of CR translate into long-term clinical outcomes, particularly improved progression-free survival and overall survival, concludes Pleyer.
Related Content:
